- Over 3,700 men in British Columbia will be diagnosed with prostate cancer this year.
- Metastatic castrate resistant prostate cancer (m-CRPC) is the lethal form of the disease and is resistant to most treatments.
- EPI-506 is a drug discovered in collaboration between Dr. Marianne Sadar at the BC Cancer Agency and UBC, and Dr. Raymond Andersen at UBC’s Department of Chemistry.
- The EPI-506 Phase I/II clinical trial is sponsored by ESSA Pharma Inc. and has both FDA and Health Canada approval for testing in humans as an investigational drug.
- The EPI-506 Phase I/II clinical trial is designed for patients with metastatic prostate cancer and will explore safety, tolerability and anti-tumour activity.
- BC Cancer Foundation donors have provided significant support of $2.6 million to advance Dr. Sadar’s research and development of a new treatment for prostate cancer.
British Columbia has over 20 Prostate Cancer Support Groups meet once a month. This group is focused on providing help to Chinese-speaking men, but everyone is welcome. We speak Mandarin, Cantonese and English. We meet on the second Thursday of every month from 7:00pm to 9:00pm at the Richmond Public Library (2/F Brighouse Main Branch, 7700 Minoru Gate, Richmond, BC V6Y 1R8). Please register online at The Richmond Public Library website (or call 604-231-6413 for registration). Join us for the professional presentation and talk to other men and family members who have been dealing with prostate cancer for weeks, months or even years.
If you want to chat with a survivor one on one, you may drop in our walking club. The Richmond Blue Walkers walk on every Tuesdays and Thursdays 9-11am, 5-10 km along the beautiful river dykes and parks in Richmond (Walk in the Richmond Shopping Centre during the raining days or cold seasons). Click here for the schedule or contact Daniel Leung at 604-836-6423 for the locations and meeting places.
This blog is provided as a public service. Any persons using the information or documents provided on the blog do so at their own risk. Reference: Oncology Guide to Reliable Websites